Medical Oncology

, Volume 15, Issue 1, pp 20–26 | Cite as

How do mutated oncogenes and tumor suppressor genes cause cancer?

  • Dan Grandér


In recent decades we have been given insight into the process that transforms a normal cell into a malignant cancer cell. It has been recognised that malignant transformation occurs through successive mutations in specific cellular genes, leading to the activation of oncogenes and inactivation of tumor suppressor genes. The further study of these genes has generated much of its excitement from the convergence of experiments addressing the genetic basis of cancer, together with cellular pathways that normally control important cellular regulatory programmes. In the present review the context in which oncogenes such as proliferation, cell death/apoptosis, differentiation and senescence will be described, as well as how these cellular programmes become deregulated in cancer due to mutations.


oncogenes tumor suppressor genes proliferation apoptosis differentiation senescence 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Palmero I, Peters G. Perturbation of cell cycle regulators in human cancer.Cancer Surv 1996;27: 351–367.PubMedGoogle Scholar
  2. 2.
    Wyllie AH. Apoptosis and carcinogenesis.Eur J Cell Biol 1997;73: 189–197.PubMedGoogle Scholar
  3. 3.
    Hayflick L. The limitedin vitro lifetime of human diploid strains.Exp Cell Res 1965;37: 614–636.PubMedCrossRefGoogle Scholar
  4. 4.
    Campisi J. Replicative senescence: An old live's tale?.Cell 1996;84: 497–500.PubMedCrossRefGoogle Scholar
  5. 5.
    Cleaver JE. It was a very good year for DNA repair.Cell 1994;76: 1–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Graña X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs).Oncogene 1995;11: 211–219.PubMedGoogle Scholar
  7. 7.
    Pardee AB. G-1 events and regulation of cell proliferation.Science 1989;246: 603–608.PubMedCrossRefGoogle Scholar
  8. 8.
    Kamb A, Gruis NA, Weaver-Feldhaus J. A cell cycle regulator potentially involved in genesis of many tumor types.Science 1994;264: 436–440.PubMedCrossRefGoogle Scholar
  9. 9.
    Yang E, Korsmeyer SJ. Molecular thanatopsis: A discourse on the BCL2 family and cell death,Blood 1996;88: 386–401.PubMedGoogle Scholar
  10. 10.
    Whyte M. ICE/CED-3 proteases in apoptosis.Cell Biol 1996;6: 245–248.Google Scholar
  11. 11.
    Fraser A, Evan G. A license to kill.Cell 1996;85: 781–784.PubMedCrossRefGoogle Scholar
  12. 12.
    Vogelstein B, Kinzler KW. p53 function and dysfunction.Cell 1992;70: 523–526.PubMedCrossRefGoogle Scholar
  13. 13.
    Olsson I, Bergh G, Ehinger M, Gullberg U. Cell differentiation in acute myeloid leukaemia.Eur J Hematol 1997;57: 1–16.CrossRefGoogle Scholar
  14. 14.
    Sachs L. Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia.Nature 1978;274: 535.PubMedCrossRefGoogle Scholar
  15. 15.
    Alcorta DA,et al. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.Proc Nat Acad Sci USA 1996;93: 13742–13747.PubMedCrossRefGoogle Scholar
  16. 16.
    Harley CB, Villeponteau B. Telomeres and telomerase in aging and cancer.Current Opinion in Genetics & Development 1995;5: 249–255.CrossRefGoogle Scholar
  17. 17.
    Jones JL, Walker RA. Cell-cell and cell-stromal interactions in breast cancer invasion and metastasis.International Journal of Oncology 1997;11: 609–616.Google Scholar

Copyright information

© Stockton Press All rights reserved 1998

Authors and Affiliations

  • Dan Grandér
    • 1
  1. 1.Research Laboratory of Radiumhemmet, CCKKarolinska HospitalStockholmSweden

Personalised recommendations